Similarly, several PI3K inhibitors which have been previously studied in ER-positive HER2-negative BC, are currently at early stages of testing in HER2-positive disease (including buparlisib (134), alpelisib (135), taselisib-NCT02390427, and pictilisib-NCT00960960). Here, ESR1 is linked to breast cancer.